Kymera Prices $223M Equity Offering At $47/Share
Kymera Therapeutics Inc (NASDAQ:KYMR) has priced its upsized underwritten public offering of 4.7 million shares at $47.00 per share, representing a discount…
72 Biggest Movers From Yesterday
Gainers
Pop Culture Group Co., Ltd (NASDAQ: CPOP) shares jumped 405% to close at $30.30 on Wednesday after the company priced its IPO at $6 per share.
29 Stocks Moving in Wednesday’s Pre-Market Session
Gainers
Bridgeline Digital, Inc. (NASDAQ: BLIN) shares rose 83% to $6.20 in pre-market trading. Bridgeline Digital shares jumped over 36% on Tuesday on above-average volume.
Kymera Therapeutics Seeks To Raise Capital Via 4M Shares Equity Offering To Fund Oncology Franchises
Kymera Therapeutics Inc (NASDAQ:KYMR) commenced an underwritten public offering of 4 million shares of common stock. Underwriters can purchase up to…
61 Biggest Movers From Yesterday
Gainers
Marin Software Incorporated (NASDAQ: MRIN) surged 96.9% to close at $7.50. Marin Software, last week, announced it has added the ability to manage Instacart Ads to its flagship MarinOne platform.
44 Stocks Moving In Monday’s Mid-Day Session
Gainers
Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares climbed 43.5% to $127.44 after the company announced positive clinical data for its CRISPR therapy.
Kymera Therapeutics Announces Positive Interim Results from Single Ascending Dose Phase 1 Trial of KT-474 Demonstrating Degrader Proof-of-Mechanism
KT-474 has achieved and exceeded Phase 1 target degradation of 85% within the SAD portion of the Phase 1 trial dosed to date, with 90% median degradation at the 300 mg dose
After single
Kymera Therapeutics Names Elaine Caughey As Chief Business Officer
Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointment
Kymera Therapeutics’ KT-413 Shows Encouraging Preclinical Anti-Cancer Activity
Kymera Therapeutics Inc (NASDAQ:KYMR) has announced new preclinical data on its IRAKIMiD degrader KT-413’s potential as both a monotherapy and in…